Genmab A/S GMAB
Genmab A/S (Nasdaq: GMAB) is an oncology drug developer. Its lead program, Epcoritamab (EPKINLY/TEPKINLY), is in Phase 3 for relapsed/refractory DLBCL and follicular lymphoma; frontline DLBCL combination in Phase 3.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Epcoritamab (EPKINLY) with AbbVie | R/R DLBCL, R/R FL (approved); 1L DLBCL, FL combinations (Phase 3) | antibody | Approved |
| Tivdak (tisotumab vedotin) with Pfizer | recurrent/metastatic cervical cancer | antibody | Approved |
| Rinatabart sesutecan (Rina-S, GEN1184) | FRa-expressing ovarian and endometrial cancers | antibody | Phase 3 |
| Petosemtamab | 1L and 2L/3L recurrent/metastatic HNSCC | antibody | Phase 3 |
| GEN1059 (BNT314) | — | antibody | Phase 1 |
| GEN3018 | — | antibody | Phase 1 |
| GEN1079 | — | antibody | Phase 1 |
| GEN1106 | — | antibody | Phase 1 |
Recent results and decisions
- Nov 5, 2026approval Epcoritamab approved in Europe as TEPKINLY in combination with R² for treatment of adult patients with relapsed or refractory FL.
Epcoritamab approved in Europe (as TEPKINLY®) and Japan (as EPKINLY®) in combination with R² for the treatment of adult patients with relapsed or refractory FL
Filing - Oct 28, 2026met Petosemtamab combination met dual primary endpoints of overall survival and objective response rate in first-line PD-L1+ HNSCC at first interim analysis.
Treatment with the petosemtamab combination demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), reducing the risk of death by 50%, and objective response rate (ORR) versus pembrolizumab.
Filing - Oct 23, 2026met Phase 3 RAINFOL-02 trial met primary endpoint of PFS and key secondary endpoint of OS with rinatabart sesutecan versus chemotherapy in platinum-resistant ovarian cancer.
Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator's choice chemotherapy
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
- Summit Therapeutics Inc. SMMT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.